recurrent ovarian cancer
Conditions
Interventions
1:exogenous endothelial progenitor cell plus Bevacizumab
2:Bevacizumab alone
Sponsors
Third military medical university
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. age: 16-60 years old; 2. patient with recurrent ovarian cancer; 3. blood routine examination is normal; 4. serum bilirubin level less than or equal to the institutional upper limits of normal (ULN), AST/ALT <=2.5 times of the ULN in patients without liver metastases; serum creatinine <= 1.5 mg/dL, urine protein < 1+ or 24 hour urine protein < 1000 mg; 5. Patients with a chemotherapy-free interval of more than 12 months from primary therapy. No more than two prior cytotoxic chemotherapies are allowed in the setting of recurrent disease; 6. Patient without liver or other distant metastasis
Exclusion criteria
Exclusion criteria: 1. Patients had prior treatment with VEGF or EGFR directed therapy; 2. Patient with Other serious illnesses, which would limit survival to <2 years, or a psychiatric condition, which would prevent compliance with treatment or informed consent; 3. Uncontrolled or severe disease which in the opinion of the treating physician would make this protocol treatment; unreasonably hazardous for the patient, such as cardiovascular disease, diabetes, pulmonary disease, etc; 4. Patient had a major surgical procedure within 28 days prior to day 1 of therapy; 5. Patients with a "currently active" second malignancy; 6. Patients who have received any investigational agent within the prior 4 weeks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| lesion size;CA125, VEGF, VEGFR level in seru; | — |
Countries
China
Contacts
Public ContactZhiqing Liang
Outcome results
None listed